Stockscreener 앱 받기
6.585
4.52%
0.285
전일 마감가:
$6.30
열려 있는:
$6.28
하루 거래량:
3.71M
Relative Volume:
0.44
시가총액:
$1.17B
수익:
$847.25M
순이익/손실:
$-284.86M
주가수익비율:
-2.8755
EPS:
-2.29
순현금흐름:
$-112.35M
1주 성능:
+1.46%
1개월 성능:
-10.29%
6개월 성능:
-18.10%
1년 성능:
-48.27%
1일 변동 폭
$6.23
$6.81
1주일 범위
$6.23
$6.81
52주 변동 폭
$5.01
$17.81
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
NVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.59 | 1.17B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.21 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.43 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
552.88 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.02 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus
Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigroup | NVAX Stock News - GuruFocus
Citi initiates Novavax stock with sell rating on strategy shift concerns - Investing.com UK
Novavax (NVAX) Receives Initial 'Sell' Rating from Citi | NVAX Stock News - GuruFocus
Novavax: New Vaccine, Same Old StoryStill A Sell (NASDAQ:NVAX) - Seeking Alpha
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
Novavax: positive results for Covid/flu vaccine - MarketScreener
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response - Yahoo Finance
Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals - The Pharma Letter
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Pipelinereview
RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report - Benzinga
Novavax at Goldman Sachs Healthcare Conference: Strategic Shift to R&D Focus - Investing.com Nigeria
RFK Jr. picks eight new members to CDC vaccine advisory panel - Seeking Alpha
Novavax's COVID-19-Influenza Combination and Stand-alone Influen - GuruFocus
Novavax (NVAX) Phase 3 Trial Shows Promising Results in Vaccine Study | NVAX Stock News - GuruFocus
Novavax reports positive results for COVID-19 and flu vaccine candidates By Investing.com - Investing.com South Africa
Transcript : Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com
Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates - Yahoo Finance
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Benzinga
Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Novavax's COVID-flu combo vaccine shows strong immune response in trial - Reuters
Novavax (NVAX) Reports Promising Results for COVID-19-Flu Vaccine Combo - GuruFocus
Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall By Investing.com - Investing.com Canada
Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study - marketscreener.com
Novavax stock gains on data for COVID-flu shot (NVAX:NASDAQ) - Seeking Alpha
Novavax reports positive results for COVID-19 and flu vaccine candidates - Investing.com Canada
Novavax (NVAX) Reports Positive Results for COVID-Influenza Comb - GuruFocus
Novavax Reports Promising Phase 3 Vaccine Trial Results - TipRanks
Novavax (NVAX) Reports Positive Results for COVID-Influenza Combo Vaccine Trial | NVAX Stock News - GuruFocus
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study - marketscreener.com
Novavax Breakthrough: Phase 3 Trial Reveals Strong Results for First-of-Kind COVID-Flu Combo Vaccine - Stock Titan
Vaccine makers steady despite RFK Jr.'s removal of CDC expert panel (PFE:NYSE) - Seeking Alpha
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel - marketscreener.com
Vaccine Stocks Stay Steady Despite US Health Shake-Up - Finimize
Recombinant Vaccine Market is Booming Worldwide with - openPR.com
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance - Benzinga
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - MSN
RFK Jr. removing, replacing all members of CDC vaccine advisory panel (MRNA:NASDAQ) - Seeking Alpha
Where are the Opportunities in (NVAX) - news.stocktradersdaily.com
Investor Network: Novavax, Inc to Host Earnings Call - ACCESS Newswire
July 25th Options Now Available For Novavax (NVAX) - Nasdaq
LigaChem Biosciences adopts U.S. Novavax technology for next-gen ADCs - Chosunbiz
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stoc - GuruFocus
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stock News - GuruFocus
RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Benzinga
Novavax to Participate in Upcoming Investor Conferences - Quantisnow
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
노바백스 주식 (NVAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
1.31%
0.62%
자본화:
|
볼륨(24시간):